EP Patent

EP2869814B1 — Pharmazeutische darreichungsformen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophen-carboxamid

Assigned to Bayer Pharma AG · Expires 2016-04-06 · 10y expired

What this patent protects

Patent listed against Keppra.

Drugs covered by this patent

Patent Metadata

Patent number
EP2869814B1
Jurisdiction
EP
Classification
—
Expires
2016-04-06
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.